Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaniprevir + Peg-IFN/RBV in treatment-experienced HCV GT1
NCT00704405Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of vaniprevir in hepatitis C (HCV) (5 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d at 72 weeks, Number of Participants Experiencing an Adverse Event at 73 weeks and 1 more. Started Mar 2009; status: completed.
02
Drugs
vaniprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00704405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704405.